Investors Hub Daily
|
Home
|
Log in
Boards
Stocks
Commodities
Forex
The Lounge
Hot!
Breakout Boards
iHub My Stocks Activity
Ticker Buzz Cloud
Top Boards
Most Read
Most Posted
Most Followed Members
Recent News
Active Boards
Site Stats
New Boards
Hot on StockWiki
Data Tools
Charts
Trader Alerts
Trades
Portfolio
Top Lists
News Alerts
Commodities
More Tools
My Image Gallery
Advanced Search
Videos
All News
Stock Screener
News Filter
Live Charts
Live News
Live Desktop
Forex Prices
Commodities
ETF Center
Online Brokers
Educational Channel
Streamer
Level 2
Home
>
Boards
>
US Listed
>
Medical - Drugs
>
Neurogenesis Inc (NEUN)
This coming up under neun - is this
Public Reply
|
Private Reply
|
Keep
|
Last Read
Post New Msg
Replies (1)
|
Next 10
|
Previous
|
Next
cintrix
Thursday, June 02, 2011 2:25:42 PM
Re:
None
Post #
of
283
This coming up under neun - is this the same company?
Neuronascent Receives State and Federal Funding for Its Neurogenesis Therapeutic
Programs
CLARKSVILLE, MD, Jun 02, 2011 (MARKETWIRE via COMTEX) -- Neuronascent, Inc.
announced today that the Company has received funding from both the federal
government, under the Qualifying Therapeutic Discovery Project for the
development of its preclinical therapeutic candidates for neurodegenerative
diseases, and from Maryland's Biotechnology Center, to accelerate development of
its neurogenic candidate for Down syndrome. The latter project is a collaboration
with Dr. Barbara Slusher, Chief Scientific Officer, Johns Hopkins University's
NeuroTranslational Brain Center.
Neuronascent aims to develop non-invasive therapeutics for central nervous system
indications with high unmet need. The company's lead compounds, currently in
preclinical testing, are developed to regenerate neurons and provide specialized
neuroprotection for newly generated and surviving neurons under neurodegenerative
diseases. These potentially disease-modifying effects aim to improve behavioral
outcomes including motor function and memory. Animal studies with these compounds
have previously shown a reversal of cognitive loss in aged mice to young levels.
"These funds will allow us to provide proof-of-principle that our neurogenic
therapeutic may be effective for Down syndrome, a new target for drug
development," said Judith Kelleher-Andersson, Ph.D., President and Chief
Scientific Officer. "These funds also afford us the opportunity to pursue
multiple preclinical studies to further develop our lead agents for clinical
trials in Alzheimer's and Parkinson's disease."
Founded in 2004 by Dr. Kelleher-Andersson, Neuronascent, Inc. is a small-molecule
central nervous system drug discovery company, developing novel therapeutics
using their neurogenesis discovery platform. Neuronascent has laboratories in
Rockville and Frederick, Maryland.
For more information contact: jkelleher@neuronascent.com
Safe Harbor Statement This release contains forward-looking statements, which are
made pursuant to the safe harbor provisions of the U.S. Private Securities
Litigation Reform Act of 1995. Forward-looking statements are commonly identified
by words such as "would," "may," "will," "expects," and other terms with similar
meaning. Forward-looking statements are based on current beliefs, assumptions and
expectations and speak only as of the date of this release and involve risks and
uncertainties that could cause actual results to differ materially from current
expectations.
Neuronascent, Inc.
Email Contact
SOURCE: Neuronascent, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=E890CFD310F31E62
Copyright 2011 Marketwire, Inc., All rights reserved.
Neurogenesis Inc (NEUN) Stock Trading Info:
Public Reply
|
Private Reply
|
Keep
|
Last Read
Post New Msg
Replies (1)
|
Next 10
|
Previous
|
Next
Follow Board
Keyboard Shortcuts
Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote
-
Discussion Board
+/- to Watchlist
© 2013 InvestorsHub.Com, Inc.